Antibody drug conjugates are the unique class of therapeutic agents which consists of three components including monoclonal antibody which targets the antigen, cytotoxic chemotherapeutic agent, and a chemical linker which bridges the two moieties together.
Global Cancer Antibody Drug Conjugate Market 2028 Report Highlights:
- Global Cancer Antibody Drug Conjugate Market USD 30 Billion Opportunity
- Global Market Sales Trends & Market Forecast Till 2028
- Market Analysis by County: US, Europe, Japan, China, South Korea, India, Australia, Taiwan, Canada
- Market by Indication: Breast Cancer, Lymphoma, Leukemia, Multiple Myeloma, Gastric Cancer, Lung Cancer
- Clinical Insight On 18 Approved Cancer Antibody Drug Conjugates
- Dosage, Price & Patent Insight On 18 Cancer Antibody Drug Conjugate
- Quarterly & Yearly Drug Sales Insight & Forecast Till 2028
- Clinical Insight On More Than 400 Cancer Drug Conjugates In Clinical Trials
- Competitive Landscape
Download Report:
https://www.kuickresearch.com/report-global-cancer-antibody-drug-conjugate-market
Antibody drug conjugates are the unique class of therapeutic agents which consists of three components including monoclonal antibody which targets the antigen, cytotoxic chemotherapeutic agent, and a chemical linker which bridges the two moieties together. The goal of antibody drug conjugate is to efficiently eliminate cells which express the target antigen and decrease systemic payload exposure. Till date, about 15 ADC have entered the global market which has been indicated for the management of wide range of hematological and solid malignancies.
Further, advancement in the field of biotechnology has enhanced the understanding about cancer biology. This has ultimately led to identification of novel targets which have therapeutic potential. Apart from Her2, clinical trials are evaluating the role of several therapeutic targets including Nectin4, Trop2, LIV1, Her3, Mesothelin, c-Met, folate receptor alpha, tissue factor, and others. The identification of therapeutic targets provides new opportunity for pharmaceutical companies to invest in this sector. For instance in 2021, Eisai and Bristol Myers Squibb announced that the companies have entered into an exclusive global strategic collaboration or the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). MORAb-202 is Eisai’s first ADC and combines Eisai’s in house developed anti-folate receptor alpha (FRα) antibody, and Eisai’s anticancer agent eribulin, using an enzyme cleavable linker.
However, the complex nature of the novel antibody drug conjugates require a team of collaborators to bring together all the different design pieces such as protein engineering, monoclonal antibody affinity targeting, and medicinal chemistry. To overcome these challenges and ease the process of drug development, researchers are jointly using both experimental animal models and computational models to improve the overall speed and efficiency of drug development of antibody-drug conjugates (ADCs) to get more of the agents on the market. Furthermore, researchers have also designed a facile and highly efficient method for synthesizing gsADCs in one-step with a disaccharide-drug substrate. The emergence of these technologies will reduce the cost of drug development and will lead to new product launches in the market during the forthcoming years.
While the majority of ADC in clinical trials is targeted towards oncology indications, ADC will also likely to expand out beyond cancer indications in other areas, such as autoimmune disorders. For instance, Blenrep and Adcetris, which target antigens expressed on immune cell populations are currently in clinical trial for several non-cancer indications. Other ADC in clinical trials is indicated for rheumatoid arthritis and infectious diseases, among other indications. The expanded approval of antibody drug conjugate in other therapeutic indications will also propel the growth of market.
As per our report findings, the global antibody drug conjugate market is expected to surpass US$ 30 Billion by 2028. Increasing emphasis on research and development therapies for cancers, such as lung cancer, colorectal cancer, multiple myeloma cancer, and prostate cancer, is likely to create significant growth opportunities of antibody drug conjugate therapy providers. Moreover, rising clinical trials and development of new and effective therapy options is also driving the growth of market. In addition to this, growing need for breakthrough therapy solutions and the effectiveness of antibody drug conjugate therapy in the management of cancer is also fueling the growth of market during forecast period.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities. The key players in the market include Takeda Pharmaceutical, Roche, Astellas Pharma, Seagen, GlaxoSmithKline, and ADC Therapeutics.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com